The prevalence and association of the founder mutations with ovarian cancer risk in the Polish population was limited to analysis of BRCA1/2 in relatively small groups of cases [12,13,14,25,31], and was not performed for other genes. This evidence concerns the gene BRCA1 and ovarian cancer.